Healthcare

Osage University Partners has contributed to a series A round for Vor Biopharma, an oncology drug developer based on work by Siddhartha Mukherjee at Columbia University.

UBC and CDRD spinout Sitka Biopharma has now lured $5.5m in total and is readying its bladder cancer treatment for initial clinical trials.

Complion collected funding from investors including the multi-university-backed Ohio Innovation Fund for its regulatory compliance software platform catered to sites conducting clinical research.

Regenerative craniofacial implant manufacturer OssDsign has amassed $19.7m altogether as it prepares to take its products based on Karolinska and Uppsala university research into new markets.

The gains came against a backdrop of falling net profits and cash reserves that will test Karolinska Development as it looks ahead to convertible debt obligations.

Spun out of Inesc Tec under a strategic agreement with Frontier IP, Insignals hopes to commercialise a surgical guidance device for brain implants to treat conditions including Parkinson's.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.